Clinical Trials

698 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT05910827 2026-05-27

A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers

398 enrolled

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell

NCT06012435 2026-05-27

A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

762 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms

NCT06346392 2026-05-27

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

592 enrolled

Gastrointestinal

Stomach Neoplasms

NCT06520345 2026-05-27

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

520 enrolled

Phase 2 Not yet recruiting

Prostatic Neoplasms

NCT07609251 2026-05-27

A Clinical Study of SCTB41 Combined With Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer（Phase II Study Ongoing）

90 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06353386 2026-05-26

MK-5684-01A

220 enrolled

Prostatic Neoplasms, Castration-Resistant

NCT06780098 2026-05-26

MK-3475-01I

144 enrolled

Lung Neoplasms

NCT05378763 2026-05-22

PINNACLE

Phase 3 Suspended

268 enrolled

NSCLC

NCT05848011 2026-05-22

A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

Phase 2 Completed

154 enrolled

Prostatic Neoplasms, Castration-Resistant

NCT06545955 2026-05-22

ABLE-22

250 enrolled

Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

NCT06925737 2026-05-22

MK-2400-001

1,440 enrolled

Prostatic Neoplasms

NCT06952504 2026-05-22

TroFuse-033

1,123 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT07213674 2026-05-22

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

750 enrolled

Prostatic Neoplasms

NCT07419295 2026-05-22

TroFuse-031

590 enrolled

Urinary Bladder Neoplasms

NCT06340568 2026-05-20

Fern-EC-01

480 enrolled

Endometrial Neoplasms

NCT02504489 2026-05-19

DUBLIN-3

Phase 3 Completed

559 enrolled 32 charts

Carcinoma, Non-Small-Cell Lung

NCT05431270 2026-05-19

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

40 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT04154956 2026-05-18

CARMEN-LC03

Phase 3 Terminated

389 enrolled 16 charts

Non-small Cell Lung Cancer Metastatic

NCT06783647 2026-05-18

A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]

230 enrolled

Advanced Solid Tumour

NCT05173142 2026-05-15

A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination With Chemotherapy or Toripalimab in Advanced Solid Tumors

Phase 1/2 Completed

190 enrolled

Gastrointestinal

Stomach Neoplasms

NCT06863272 2026-05-15

IDeate-Prostate02

360 enrolled

Neoplasm Metastasis, Prostatic Neoplasms, Castration-Resistant

NCT07415031 2026-05-15

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

170 enrolled

Phase 1/2 Not yet recruiting

Solid Tumors

NCT07590934 2026-05-15

PROSPECTOR

152 enrolled

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT06445400 2026-05-13

A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer

83 enrolled

Breast

HER2-positive Breast Cancer

NCT03337698 2026-05-12

Morpheus Lung

Phase 1/2 Terminated

314 enrolled 31 charts

Carcinoma, Non-Small-Cell Lung

NCT06074588 2026-05-12

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

556 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03390504 2026-05-11

THOR

629 enrolled 32 charts

Urothelial Cancer

NCT07225946 2026-05-11

KLK2-PASenger

800 enrolled

Phase 2 Active not recruiting

Prostatic Neoplasms, Castration-Resistant

NCT05631262 2026-05-08

SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors

321 enrolled

Selected Subjects With Advanced Solid Tumors

NCT05818683 2026-05-08

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

Phase 1 Recruiting

300 enrolled

Metastatic Castration-resistant Prostate Neoplasms

NCT05954312 2026-05-08

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

Phase 1 Recruiting

290 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Neoplasms

NCT05089734 2026-05-07

EVOKE-01

603 enrolled 20 charts

Carcinoma, Non-Small-Cell Lung

NCT06764485 2026-05-06

rechARge

960 enrolled

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT06989112 2026-05-06

DE-01

600 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Neoplasms, Endometrial Neoplasms

NCT07287150 2026-05-06

InavoPC

100 enrolled

Metastatic Castration-Resistant Prostate Cancer

NCT05005728 2026-05-05

XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 2 Completed

72 enrolled

Phase 1/2 Active not recruiting

Prostatic Neoplasms

NCT05083481 2026-05-05

A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors

226 enrolled

Advanced Solid Tumors

NCT05173987 2026-05-05

KEYNOTE-C93

280 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT06551324 2026-05-05

MEVPRO-1

600 enrolled

Prostatic Neoplasms, Recurrence

NCT06635824 2026-05-05

Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

191 enrolled

Lung Neoplasms

NCT06745908 2026-05-05

Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In

507 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07365995 2026-05-05

A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

736 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT03740165 2026-05-04

KEYLYNK-001

Phase 3 Completed

1,367 enrolled 29 charts

Phase 3 Not yet recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT07524257 2026-05-04

Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Line Advanced or Metastatic NSCLC

494 enrolled

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07566052 2026-05-04

A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation

356 enrolled

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06120075 2026-05-01

ARC-27

91 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02486718 2026-04-30

Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]

1,280 enrolled 24 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT04303780 2026-04-30

Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).

345 enrolled 11 charts